Patent US5773418A successfully refreshed from Google Patents.
US5773418A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Fibrin sealant compositions and methods for utilizing same
Assignee: VIVOLUTION AS
•
Filing: 1997-11-20
•
Granted: 1998-06-30
•
Expires: 2017-11-20
Abstract
Abstract The subject invention relates to fibrin sealants. More specifically, the subject invention relates to the use of a fibrin sealant wherein a composition comprising fibrin monomer or a composition comprising noncrosslinked fibrin is utilized as a component of the fibrin sealant.
Inventors
- 👤 Peter A. D. Edwardson
- 👤 John E. Fairbrother
- 👤 Ronald S. Gardner
- 👤 Derek A. Hollingsbee
- 👤 Stewart A. Cederholm-Williams
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 06:26
CPC Classifications
C; C12; C12N; C12N11/00; C12N11/02; C12N11/10; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/36; A61K38/363; A61K38/43; A61K38/45; A61K38/46; A61K38/48; A61K38/482; A61K38/4833; A61L; A61L15/00; A61L15/16; A61L15/22; A61L15/32; A61L17/00; A61L17/005; A61L24/00; A61L24/001; A61L24/0015; A61L24/04; A61L24/10; A61L24/106; A61L27/00; A61L27/14; A61L27/22; A61L27/225; A61P; A61P7/00; A61P7/04; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/75; C12N11/06; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/254; A61L2300/40; A61L2300/404; A61L2300/406; A61L2300/416; A61L2300/418; A61L2300/45
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
67 words
A method of applying an adjuvant selected from the group consisting of antibiotics, anticancer agents, histamine H 2 -antagonists, fibronectin and fibrinolytic inhibitors to a desired site with a fibrin sealant comprising a fibrin polymer, the method comprising co-applying said adjuvant with nondynamic fibrin monomer; and converting said fibrin monomer to said fibrin polymer concurrently with said co-applying step whereby fibrin sealant with an adjuvant is provided.
Claim 2
Independent Claim
67 words
A method of applying an adjuvant selected from the group consisting of antibiotics, anticancer agents, histamine H 2 -antagonists, fibronectin and fibrinolytic inhibitors to a desired site with a fibrin sealant comprising a fibrin polymer, the method comprising co-applying said adjuvant with nondynamic fibrin monomer; and converting said fibrin monomer to said fibrin polymer concurrently with said co-applying step whereby fibrin sealant with an adjuvant is provided.
Claim 3
Dependent Claim
42 words
A composition comprising a fibrin sealant and an adjuvant selected from the group consisting of antibiotics, anticancer agents, histamine H 2 -antagonists, fibronectin and fibrinolytic inhibitors, wherein said fibrin sealant is formed by converting a nondynamic non-crosslinked fibrin to a cross-linked fibrin.
Claim 4
Dependent Claim
42 words
A composition comprising a fibrin sealant and an adjuvant selected from the group consisting of antibiotics, anticancer agents, histamine H 2 -antagonists, fibronectin and fibrinolytic inhibitors, wherein said fibrin sealant is formed by converting a nondynamic non-crosslinked fibrin to a cross-linked fibrin.
Claim 5
Dependent Claim
105 words
A composition to be applied to a desired site comprising a fibrin sealant and an adjuvant selected from the group consisting of antibiotics, anticancer agent, histamine H 2 -antagonists, fibronectin and fibrinolytic inhibitors, wherein said fibrin sealant is formed by the steps comprising: (a) adding to fibrinogen an enzyme which catalyzes the cleavage of fibrinopeptide A and/or B from said fibrinogen; (b) substantially removing said added enzyme from the product of step (a); and (c) applying the product of step (b) to the site to form said sealant such that a fibrin sealant including said adjuvant and substantially free of said added enzyme is provided.
Claim 6
Dependent Claim
105 words
A composition to be applied to a desired site comprising a fibrin sealant and an adjuvant selected from the group consisting of antibiotics, anticancer agent, histamine H 2 -antagonists, fibronectin and fibrinolytic inhibitors, wherein said fibrin sealant is formed by the steps comprising: (a) adding to fibrinogen an enzyme which catalyzes the cleavage of fibrinopeptide A and/or B from said fibrinogen; (b) substantially removing said added enzyme from the product of step (a); and (c) applying the product of step (b) to the site to form said sealant such that a fibrin sealant including said adjuvant and substantially free of said added enzyme is provided.
References Cited (Backward Citations)
US2533004A
Cited
US4442650A
Cited
US4442651A
Cited
US4377572A
Cited
US4488198A
Cited
EP0068149A2
Cited
US4442655A
Cited
US4627879A
Cited
WO1986001814A1
Cited
US4928603A
Cited
US4957903A
Cited
US4714457A
Cited
WO1988002259A1
Cited
US4709037A
Cited
US5175087A
Cited
US4909251A
Cited
WO1990004786A1
Cited
JPH02129234A
Cited
US5026785A
Cited
EP0423938B1
Cited
US5252743A
Cited
WO1991009573A1
Cited
WO1991009641A1
Cited
US5030215A
Cited
US5185001A
Cited
EP0472205A1
Cited
US5180825A
Cited
WO1992015341A1
Cited
EP0534178A2
Cited
WO1994020133A1
Cited
WO1998019805A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-06-29 | 2001-12-29 | 2002-06-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-06-29 | 2005-12-29 | 2006-06-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-06-29 | 2009-12-29 | 2010-06-30 | $7700.00 | Window Closed / Lapsed |